key: cord-0858088-4gof1yl8 authors: Lima-Morales, René; Méndez-Hernández, Pablo; Flores, Yvonne N.; Osorno-Romero, Patricia; Cuecuecha-Rugerio, Elizabeth; Nava-Zamora, Adrián; Hernández-Galdamez, Diego Rolando; Romo-Dueñas, Daniela Karola; Salmerón, Jorge title: Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico date: 2021-02-10 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.02.014 sha: a9f20083ba334fa35ff1ef4d75171a90b0aae2e9 doc_id: 858088 cord_uid: 4gof1yl8 Objective There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. The aim of this study was to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast and Acetylsalicylic Acid (“TNR4” therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Design and Methods A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18 to 80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment. Results Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. Likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group. Conclusions TNR4 therapy improved recovery and prevented risk of hospitalization and death among ambulatory COVID-19 cases. The novel coronavirus SARS-CoV-2 is characterized by a significant morbidity and mortality (Jean et al., 2020; , with no proven prevention or treatment therapies (Baud et al., 2020) . In some cases, SARS-CoV-2 can generate an exaggerated immune response that is characterized by a decreased quantity of lymphocytes, increased cytokine expression, as well as a greater risk of cardiovascular complications due to endotheliitis in several organs (Varga et al., 2020) and Disseminated Intravascular Coagulation (DIC), which are both highly related with COVID-19 deaths (Tang et al., 2020) . The impaired and overactive immune responses in COVID-19 patients is the result of cytokine dysregulation, which causes tissue inflammation, and subsequent severe lung and systemic inflammation . Recent research has shown that severe cases are associated with an increase in inflammatory cytokines such as IL-1β, IL-6, IL-8, IL-12, IFN-γ, GM-CSF, TNF-α (Huang et al., 2020) , and lymphopenia, which is characterized by a reduction in the number of CD4+ and CD8+ T cells (Guan et al., 2020; Huang et al., 2020) . Moreover, SARS-CoV-2 infection causes endotheliitis in several organs as a direct consequence of the host inflammatory response (Tang et al., 2020) . Cardiovascular complications are a major risk, since SARS-CoV-2 infects the host using the angiotensin converting enzyme 2 (ACE2) receptor, which is present in the lungs, heart, kidneys, intestines, and in endothelial cells (Tang et al., 2020) . The role of the immune system must be examined to better understand the molecular mechanisms of SARSCoV-2 pathogenesis, and to evaluate therapeutic intervention strategies that target the immune system response and complications due to endotheliitis in several organs. For this reason, therapies should focus on stabilizing the endothelium while tackling viral replication, particularly with anti-inflammatory anti-cytokine drugs, ACE inhibitors, and statins (Anderson et al., 1995; David et al., 2002; Fang et al., 2020; Feldmann et al., 2020; Flamer et al., 2008; Taddei et al., 1998) . Despite the urgent need for effective COVID-19 treatment strategies, there is no consensus about what specific treatments are best. The most common treatments for COVID-19 have been anti-inflammatory agents, antiviral therapies, and other medications with proven efficacy against viruses (hydroxychloroquine, chloroquine and ivermectin) (Poduri et al., 2020; Caly et al., 2020; Gupta et al., 2020; Tsang et al., 2020) . Other treatments include antibiotics such as Azithromycin (Bleyzac et al., 2020; Jean et al., 2020) , Tocilizumab, which may have a clinical benefit because of its anti-IL-6 nature, cellular therapy (Mesenchymal stem cells), and immunotherapy (Convalescent plasma therapy). Combination therapies, such as a triple combination of interferon beta-1b, lopinavirritonavir and ribavirin (Hung et al., 2020) , or hydroxychloroquine plus azithromycin, have also shown promising clinical improvement (Tsang et al., 2020) . Antiviral therapy has been used to deter viruses from entering cells and prevent them from multiplying or moving to other cells (Abd El-Aziz et al., 2020) . The most commonly used antivirals include Lopinavir/Ritonavir (Cao et al., 2020) , Remdesivir (Beigel et al., 2020; Wang et al., 2020) , and Favipiravir (Cai et al., 2020) . Hydroxychloroquine and Chloroquine J o u r n a l P r e -p r o o f have used in combination with Remdesivir for the treatment of hospitalized patients with COVID-19 (Poduri et al., 2020) , and a Chinese study found that Chloroquine was able to inhibit the exacerbation of pneumonia (Gao et al., 2020) . Antibiotics have mainly been used to treat secondary bacterial infections (Abd El-Aziz et al., 2020). However, Azithromycin has also shown anti-inflammatory and immunomodulatory effects against viral infections (Bleyzac et al., 2020; Jean et al., 2020) . During the acute phase of SARS-CoV-2 infection, Azithromycin may regulate and reduce the production of pro-inflammatory cytokines such as interleukin 1 beta, 6, 8, 10, 12 and TNF alpha. In the resolution phase, this drug had demonstrated an increase in neutrophil apoptosis and oxidative stress. Azithromycin has also shown beneficial effects against other types of coronavirus, by decreasing viral proliferation (Bleyzac et al., 2020; Pani et al., 2020) . Since Azithromycin works favorably in the lung parenchyma, it can act prophylactically to prevent co-infection by bacterial agents and SARS-CoV-2. Like Ivermectin, Azithromycin has also demonstrated anti-inflammatory activity, and can be a useful treatment during the mild and moderate stages of SARS-CoV-2 infection (Bleyzac et al., 2020; Damle et al., 2020) . Ivermectin is another promising therapeutic option that can effectively limit infections caused by RNA viruses and is highly capable of reducing viral replication through protein inhibition. In clinical studies, ivermectin has resulted in a viral clearance of SARS-CoV-2 from between 93% to 98% in cells (Caly et al., 2020; Gupta et al., 2020) . Ivermectin produces a modulation of the host's immune system by increasing levels of C-reactive protein, reducing the production of TNF alpha and interleukin 1-6, as well as the activation J o u r n a l P r e -p r o o f of neutrophils. It has also shown an anti-inflammatory effect at the lung parenchyma level by reducing the production of IgE and IgG1 cytokines in bronchial cells. Since ivermectin can reduce viral replication and the release of pro-inflammatory cytokines, this drug has produced a good response in the non-severe clinical stages of COVID-19 (Gupta et al., 2020; Portmann-Baracco et al., 2020) . Montelukast is a potent cysteinyl leukotriene receptor antagonist that reduces protein expression of IL-4, IL-5, and IL-13 in the lungs, and exerts its anti-inflammatory effect through the suppression of T-helper type-2 cytokines (Fidan et al., 2020) . Montelukast may have an immune modulatory role and inhibitory effect on bradykinin, as well as a bronchoconstrictive effect, secondary to the interaction of the SARS-CoV-2 virus and the receptors of the ACE2 (Almerie et al., 2020; Fidan et al., 2020) . Moreover, some studies have detected a significant reduction in SARS-CoV-2 infection among elderly patients with asthma who are treated with montelukast (Bozek et al., 2020) . The cytokine storm triggered by SARS-CoV-2 infection causes a state of hypercoagulability and platelet hyperaggregation that can lead to DIC, venous and arterial thrombosis, and microvascular thrombosis (Bianconi et al., 2020) . Acetylsalicylic acid (ASA) has been used as an anti-inflammatory and antithrombotic medication in patients with severe COVID-19. A clinical trial involving antiplatelet therapy that included ASA and clopidogrel found an improved ventilation/perfusion ratio in COVID-19 patients with severe respiratory failure (Viecca et al., 2020) . Currently, there is a pressing need for effective treatments that can prevent or attenuate lung and systemic inflammation, as well as endotheliitis and thrombosis, in order to prevent the severity of health complications related to COVID-19. The aim of this study was to assess the effectiveness of a multidrug therapy: "TNR4" (Ivermectin, Azithromycin, Montelukast and ASA), on the health recovery, risk of hospitalization and death, in a sample of ambulatory COVID-19 cases in Tlaxcala, Mexico. A comparative effectiveness study was performed among patients with laboratory- Suspected COVID-19 cases were evaluated by medical personnel from primary healthcare units or epidemiologists from public hospitals, using a COVID-19 early identification/triage. Persons with acute respiratory illness and sudden onset of at least one of the following symptoms: cough, sore throat, shortness of breath or fever [≥ 38°C (measured) or history of fever (subjective)] irrespective of admission status were considered suspected cases. Other criteria included having at least one of the following during the 14 days prior to onset of symptoms: (1) close contact with a confirmed or probable case of SARS-CoV-2 infection; (2) travel to areas with local transmission of SARS-CoV-2; (3) worked in, or attended, a health care facility where patients with SARS-CoV-2 infections were being treated; or (4) was admitted with severe pneumonia of unknown aetiology (World Health Organization, 2020b). From May 11 to September 9, 2020, a total of 6,798 laboratory-confirmed COVID-19 cases were reported in the state of Tlaxcala, and 3,399 of these cases were treated at the Tlaxcala Ministry of Health. Of these cases, 1,147 were eligible ambulatory patients who presented mild or moderate symptoms of COVID-19 and were invited to participate in this study. Patients excluded from this study, were those who refused participate (n=251), who were under 18 years or older than 80 years (n=44), and those who initiated the treatment on the same day or one day before they were hospitalized or died (n=84). The study population consisted of 768 COVID-19 patients who accepted to be clinically evaluated for 14 days, 481 accepted to receive the TNR4 therapy. The other 287 patients agreed to the clinical follow-up, but did not receive the TNR4 therapy because they had already been offered another treatment, they had self-medicated for cold and flu symptoms, or were asymptomatic, so they did not think further treatment was necessary (Figure 1 ). The effectiveness of TNR4 and the therapies used in the comparison group was measured by means of next health outcomes: percentage of patients who completely recovered within the first 14 days after their symptoms began, and risk of hospitalization or death. Participants were also asked if they experienced any undesirable side effects from each of the TNR4 medications, as well as for the medications used in the comparison group. Differences between the TNR4 and comparison group were determined based on sociodemographic variables, occupation, prevalence of comorbidities, smoking, pregnancy, and average days elapsed between the onset of symptoms and therapy initiation. For continuous variables we calculated the difference between means using linear regression, and for categorical variables we obtained the difference between proportions using chi squared tests. Difference of proportions were also performed to compare the percentage of COVID-19 patients who recovered their health within 14 days after the onset of symptoms, between TNR4 versus the comparison group. These analyses were adjusted by age, sex, occupation, and comorbidities, and were additionally stratified by comorbidities, age groups (in tertials), and sex. We also compared the likelihood of occurrence of specific health outcomes, e.g. recovery within the first 14 days after the onset of symptoms, hospitalization, and death, in the TNR4 and the comparison groups. These probabilities were estimated using multivariate logistic regression models and 95% Confidence Intervals (CI's), which were adjusted by age, sex, comorbidities, and occupation. Finally, we assessed the percentage of undesirable side effects associated with each of the TNR4 medications, and any other medications that were used by the patients who were primarily treated with TNR4. Additionally, we identified the type of medications or therapies that were used by participants who did not accept the TNR4 therapy. All statistical analyses were performed using Stata SE version 15.0 software. Table 1 presents a comparison of the sociodemographic variables, occupation, comorbidities, and average days from onset of symptoms and therapy initiation, between both treatment groups. Participants in the TNR4 group were 4.9 years younger than those in the comparison group, were 10.3% less likely to be male, had 7.1% lower prevalence of any comorbidity, and were 8.4% more likely to be health workers (p≤0.050, in all cases). The percentage of hospitalized participants was significantly lower among those who took TNR4 therapy, than in the comparison group. This was observed in all sub-groups (p values ≤0.010, in all groups). The percentage of participants who died was also significantly lower J o u r n a l P r e -p r o o f among the TNR4 treatment than in the comparison group for all sub-groups: patients with comorbidities, older participants, males, and health workers (p≤0.027 in all groups). The likelihood of the three outcomes of interest: fully recovering, being hospitalized, or dying within 14 days after the onset of symptoms, are reported in Table 3 . All analyses were stratified by comorbidities, age, sex, and occupation. In the total study population, participants in the TNR4 group had a 3.4 times greater likelihood of making a full recovery, than those in the comparison group. The same result was observed in the study sub-groups: a 3.5-fold higher likelihood of recovery among people with comorbidities; a 3.0 and 4.0 times greater probability of fully recovering in the younger and older age groups; and a 3.9 and 1.9 higher likelihood of recovery among males and health workers (p≤0.005 in all groups, except for health workers group). Among the total study population, the risk of being hospitalized was 75% lower among participants treated with TNR4 (OR: 0.25). Patients with comorbidities also had an 76% lower risk of hospitalization (OR: 0.24); younger (77%) and older (68%) participants had a lower risk as well (OR: 0.23, and 0.32, respectively); as did males and health workers who had an 76% and 66% lower risk of being hospitalized (OR: 0.24 and 0.34, respectively) than those in the comparison group (p values ≤0.000 in all groups, except for health workers group). Patients treated with TNR4 had an 81% lower risk of death among the total study population (OR: 0.19). Patients with comorbidities also had an 78% lower risk of dying (OR: 0.22); the risk was also 94% and 78% lower among middle-age and older participants J o u r n a l P r e -p r o o f (OR: 0.06, and 0.22, respectively); and an 82% lower risk was observed among males (OR: 0.18), in relation to the comparison group (p values were ≤0.008 in all groups). Montelukast; while abdominal pain and nausea (0.8%) were associated with ASA. The most frequently reported adverse effects from the combined medications were: gastrointestinal issues such as abdominal pain, nausea, vomiting, diarrhea, constipation, diarrhea and constipation (5.9%), headache and dizziness (3.1%), asthenia, fatigue, and confusion (1.4%), and urticarial and itchy feeling (0.9%). Most patients who received the TNR4 medications did not use any other treatment (89.8%), however, some of them reported taking the following medications: 2.71% used nonsteroidal anti-inflammatory drugs (NSAIDs), 1.90% took medications to treat cold and flu symptoms, 0.9% used antibiotics, and 0.74% used antivirals. The COVID-19 patients who did not receive the TNR4 treatment reported the following: 19% did not take any medications, 61.4% used NSAIDs, 14.4% combined antibiotics with NSAIDs or corticosteroids, and 5.2% took antiviral drugs along with NSAIDs or corticosteroids. The results of our study indicate that the combination of Ivermectin, Azithromycin, Montelukast and Acetylsalicylic acid, significantly increases the likelihood of a full recovery within 14 days after the onset of symptoms, and decreases the risk of hospitalization or death among ambulatory cases of COVID-19 in the state of Tlaxcala, Mexico. The participants who received the TNR4 treatment had a significantly lower prevalence of comorbidities, and higher proportion of them were younger, male and healthcare professionals than the comparison group, which may have also influenced the improved health outcomes we observed in this group. There is limited clinical evidences regarding the effectiveness of multidrug treatments that can significantly improve health outcomes in COVID-19 patients (Ortega et al., 2020; Sanders et al., 2020) . A descriptive metanalysis of 689 trials conducted in 2020 reports that the most frequently used treatments were antivirals (n=144), antimalarials (n=112), hydroxychloroquine alone (n=110), antibiotic/anti-parasitic drugs (n=34), and trials with Azithromycin (n=28) (Janiaud et al., 2020) . To the best of our knowledge, no published studies have investigated the combined effect of the four drugs used in the TNR4 treatment, but others have examined at least two of the medications we tested as part of this study. For example, a Randomized Clinical Trial (RCT) conducted in Brazil among 504 cases of mild to moderate COVID-19, reported that patients treated with Hydroxychloroquine alone, or with Azithromycin during 15 days, showed no clinical improvement, instead they reported more adverse effects in the treatment groups than among patients who received the standard of care (Cavalcanti et al., 2020) . In contrast, a Chinese study found that chloroquine effectively stopped the exacerbation of pneumonia, improving lung imaging and shortening the disease course, compared with the control treatment (Gao et al., 2020) . However, the use of this medication is limited due its cardiovascular toxicity and other safety concerns (Tsang et al., 2020) . A retrospective cohort study of 1,438 hospitalized patients with COVID-19 in New York, USA, reported that the likelihood of death among patients treated with Hydroxychloroquine alone was 1.08, for Azithromycin alone it was 0.56, and for a combination of both medications it was 1.35. However, these results were not statistically significant (Rosenberg et al., 2020) . In contrast, a multicenter retrospective study in Michigan evaluated 2,541 hospitalized patients with COVID-19, and found a significant survival benefit of 66% among those who received hydroxychloroquine alone, and 71% among those who were treated with Hydroxychloroquine plus Azithromycin, compared to those who did not receive either drug (Arshad et al., 2020) . Recent studies that examined the efficacy of Ivermectin have shown antiviral activity for many viral infections (Jabeen et al., 2020) . A retrospective analysis of consecutive patients with COVID-19 from four hospitals in Florida, USA, compared 173 patients who received Ivermectin plus Hydroxychloroquine, or Hydroxychloroquine with Azithromycin, versus 103 patients who received usual care plus Hydroxychloroquine, or Hydroxychloroquine with Azithromycin. All-cause mortality was lower in the Ivermectin group than in the usual care (OR 0.27; p=0.03), and the proportion of patients who were successfully extubated was higher in the Ivermectin group (36%) than in the usual care (15%) (p=0.07) (Rajter et al., 2020) . The results of our study indicate that patients who received the TNR4 treatment had an 81% lower risk of death, while even older patients and those with comorbidities reduced their risk by 78%. The IDEA (Ivermectin, Dexamethasone, Enoxaparin and Aspirin) Study, which investigated 167 mild to severe COVID-19 patients from Argentina, found that none of the mild or moderate cases of COVID-19 who received the experimental treatment were hospitalized, and only one patient died (0.59%) (Carvallo et al., 2020) . By comparison, the TNR4 therapy resulted in a higher mortality, with 67 patients who died (8.7%) from a total of 768 participants., The use of ASA among patients with has been associated with reduced thrombo-inflammation and a lower risk of clinical complications and mortality. A recent systematic review reports that ASA has demonstrated anti-inflammatory, antithrombotic effects, and a significant ASA-mediated antiviral activity against DNA and RNA viruses, including different human coronaviruses (Bianconi et al., 2020) . To date, it is still unclear whether multidrug therapies against COVID-19 infection can provide additional benefits over monotherapy, since drug-drug interaction may further worsen the clinical outcomes of COVID-19 patients, especially among those with comorbidities (Awortwe et al., 2020; Back et al., 2020) . In this context, our study has some important strengths and weakness that should be considered. First, we were unable to identify the specific therapeutic effect of each TNR4 drug against COVID-19, since they were not administered separately, however, participants were asked to report how many drugs they took, and if they experienced any side effects from each of the TNR4 therapy: nearly 90% of the participants indicated no undesirable effects from any of the four drugs. Second, our study focused on ambulatory patients, so we were unable to collect specific clinical measures such as oxygen saturation, radiographic findings, laboratory studies, and bacteriology or virology cultures. Nonetheless, we did obtain detailed information regarding the use of TNR4 or other pharmacological drugs, including the time of drug intake, undesirable effects, symptoms, and health recovery from all study participants. Each COVID-19 patient was contacted through a daily phone call or home visit to reduce the probability of introducing information biases, and to compare the survival and health outcomes among study groups. Hospitalization and mortality information was obtained and verified from the national database of the Epidemiological Surveillance System for Viral Respiratory Diseases (Gobierno de México, 2020). Our findings indicate that use of the TNR4 multidrug therapy can improve the recovery, and reduce the risk of more severe disease among ambulatory cases of COVID-19. However, future research efforts are required to design and conduct RCTs to further assess the effectiveness of TNR4, in the context of different treatments schemes and healthcare settings. None, Internal Support: Ministry of Health of the Tlaxcala state, Mexico. Approval for this study was granted by the Ministry of Health of the Tlaxcala state, Mexico (#CEI02092020). J o u r n a l P r e -p r o o f May 11 to September 19, 2020 6,798 laboratory-confirmed COVID-19 cases reported in Tlaxcala. -3,399 cases were treated at the Tlaxcala Ministry of health (50%). -1,147 cases were treated as ambulatory patients at the Tlaxcala Ministry of Health and were invited to participate in this study. These participants underwent various other types of treatment, and agreed to be followed up for 14 days by health professionals at the Tlaxcala Ministry of Health. These participants received the TNR4 therapy: (1) Ivermectin, (2) Montelukast, (3) Azithromycin, and (4) Acetylsalicylic acid; and were followed up for 14 days. -251 cases refused to participate -44 cases were under 18 years or older than 80 years -75 cases started the treatment on the same day or one day before they were hospitalized -9 cases started the treatment on the same day or one day before they died - Table 3 . Likelihood of recovery, hospitalization, or death during the first 14 days after the onset of COVID-19 symptoms, among cases treated with TNR4 versus those in the comparison group. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) -an update on the status The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast The Effect of Cholesterol-Lowering and Antioxidant Therapy on Endothelium-Dependent Coronary Vasomotion Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions Real estimates of mortality following COVID-19 infection Remdesivir for the Treatment of Covid-19 -Preliminary Report Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? Drugs Azithromycin for COVID-19: More Than Just an Antimicrobial? Montelukast's ability to fight COVID-19 infection Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19 Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19 Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 Comisión Federal para la Protección contra Riesgos Sanitarios. Bases de datos de licencias sanitarias de Insumos para la Salud Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19 Anti-Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed As a potential treatment of COVID-19: Montelukast. Med Hypotheses Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Datos Abiertos de México -Información referente a casos COVID-19 Clinical Characteristics of Coronavirus Disease 2019 in China Ivermectin: potential candidate for the treatment of Covid 19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial A review on the antiparasitic drug ivermectin for various viral infections and possibilities of using it for novel Severe Acute Respiratory Syndrome Coronavirus 2: New hope to treat coronavirus disease-2019 The worldwide clinical trial research response to the COVID-19 pandemic -the first 100 days Treatment options for COVID-19: The reality and challenges SARS-CoV-2 infection-induced immune responses: Friends or foes? Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies Macrolides and viral infections: focus on azithromycin in COVID-19 pathology Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19 Antiviral and anti-inflmatory of ibvermectin and is potential use in COVID-19 ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review NORMA Oficial Mexicana NOM-017-SSA2-2012, Para la vigilancia epidemiológica. Gobierno de México Lineamiento estandarizado para la vigilancia epidemiológica y por laboratorio de la enfermedad respiratoria viral Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies Endothelial cell infection and endotheliitis in COVID-19 Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Contact tracing in the context of COVID-19 Comparison group: participants who did not accept the TNR4 treatment because they were asymptomatic, were already taking another treatment, or they had self-medicated for cold and flu. However, they agreed to take part in the follow up portion of the study. 95% Confidence Intervals (CIS) were estimated with multivariate logistic regression models The authors declare no conflict of interest in this article.